Yeast secretory expression of insulin precursors

  title={Yeast secretory expression of insulin precursors},
  author={Thomas B Kjeldsen},
  journal={Applied Microbiology and Biotechnology},
  • T. Kjeldsen
  • Published 1 September 2000
  • Biology
  • Applied Microbiology and Biotechnology
Abstract Since the 1980s, recombinant human insulin for the treatment of diabetes mellitus has been produced using either the yeast Saccharomyces cerevisiae or the prokaryote Escherichia coli. Here, development of the insulin secretory expression system in S. cerevisiae and its subsequent optimisation is described. Expression of proinsulin in S. cerevisiae does not result in efficient secretion of proinsulin or insulin. However, expression of a cDNA encoding a proinsulin-like molecule with… 

Secretory expression of human insulin precursor in Pichia pastoris employing truncated α-factor leader sequence and a short C-peptide

This study attempted to express the insulin precursor (IP) in P. pastoris using a synthetic IP-encoding gene constructed in frame with the truncated α-factor secretory signal and a short C-peptide linked A- and B-chain of human insulin in a pD902 expression vector.

Construction of a full length α-factor secretory signal sequence for human insulin precursor expression in Pichia pastoris

The full-length α-factor (α-mating factor) secretory signal of S. cerevisiae was isolated in a pTA2 cloning vector and inserted into the IP-cassette of pD902-IP and transformed into E. coli TOP10.

Development of synthetic signal sequences for heterologous protein secretion from Saccharomyces cerevisiae

It is hypothesised that the unexpected differences between the enzymes secreted and the activity of the secreted enzymes are due to additional interactions of the leader with its passenger protein.

Engineering-enhanced Protein Secretory Expression in Yeast with Application to Insulin* 210

A rational strategy to optimize the secretion efficiency in yeast of an insulin precursor by structure-based engineering of the folding stability is described and the precursor remains fully in vitro convertible to mature fast-acting insulin.

Expression of antibody fragments in Saccharomyces cerevisiae strains evolved for enhanced protein secretion

It was found that the secretion of Ran and Nan was positively correlated with the strains’ secretory capacity, while Pex was most efficiently secreted in the parental strain, while RNA-seq analysis was performed, which indicates that there are unique physiological needs for each antibody fragment secretion.

The challenge of improved secretory production of active pharmaceutical ingredients in Saccharomyces cerevisiae: A case study on human insulin analogs

Two human insulin analog precursors with minor differences in their amino acid sequences were used as model secretory proteins and suggested a difference in conformational stability, induced by the amino acid substitution, resulted in disparity in trafficking through the secretory pathway and thus a large difference in secretion yields.

Expression and Purification of C-Peptide Containing Insulin Using Pichia pastoris Expression System

In vivo efficacy studies in streptozotocin induced diabetic mice confirmed the activity of recombinant insulin and a biologically active human proinsulin along with C-peptide was expressed at high level using Pichia pastoris expression system.

Behavior in the Eukaryotic Secretory Pathway of Insulin-containing Fusion Proteins and Single-chain Insulins Bearing Various B-chain Mutations*

It is concluded that analyses of the intracellular trafficking of certain oligomerization-defective insulin mutants is complicated by the formation of disulfide isomers in the secretory pathway.

Metabolic engineering of recombinant protein secretion by Saccharomyces cerevisiae.

In this review, the protein post-translational modification such as folding, trafficking, and secretion, steps that are traditionally studied in isolation will here be described in the context of the whole system of protein secretion.